eCTD lifecycle management
Message from the Regulators: Pharmacovigilance to Move Heavily into Risk-Benefit Assessment
November 25 by Pharma IQPilar Carrero Director of Safety Medical Writing at Novo Nordisk, joins Andrea Charles from Pharma IQ, to discuss the impact social media has had on drug safety and risk managment and the dawn...
Industry View: Consequences of the New Variations Regulation for the ECTD
November 25 by Pharma IQElectronic submissions can substantially reduce submission time, allowing for a quicker release of products onto the market. However, the implementation and handling of eCTD can be problematic...